Orchid BioSciences grants license to Quest Diagnostics
Orchid received an upfront payment and will earn royalties on all diagnostic services performed by Quest Diagnostics using Orchid technology under this agreement. Further details were not disclosed.
"This agreement with Quest Diagnostics is highly significant for Orchid on several fronts," said Donald R. Marvin, chief operating officer of Orchid and acting general manager of Orchid Diagnostics, a newly formed strategic business unit at the company. "It is the first license of our market leading SNP scoring technology to the diagnostics field, and we are especially pleased that our collaborator is Quest Diagnostics, the leading provider of diagnostic services in the U.S. and an acknowledged diagnostics innovator."
Quest Diagnostics is the first laboratory to obtain a license to offer commercial genotyping services using Orchid's SNP-IT technology. SNAPshot assays based on the Orchid technology are particularly suitable for high-volume tests involving three to five SNP markers. Quest Diagnostics will develop new diagnostic tests using Orchid's SNP-IT technology embedded in SNAPshot reagent kits marketed by Applied Biosystems Group.
Most read news
Other news from the department research and development
These products might interest you
Milli-Q® Services / MyMilli-Q™ by Merck Life Science
Services & Support for Water Purification Systems
Quality Care, Delivered. In Person & Online
Good Weighing Practice by Mettler-Toledo
Your Concrete Weighing Quality Assurance Plan
GWP Verification service
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.